NCT01870440View on ClinicalTrials.gov

TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema

PHASE4CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Macular EdemaUveitis

Interventions

DRUG

Ozurdex Intravitreal Injection (0.7 mg)

Intravitreal Injection

Trial Locations (1)

94040

Northern California Retina Vitreous Associates, Mountain View

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Allergan

INDUSTRY

lead

Northern California Retina Vitreous Associates

OTHER

NCT01870440 - TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema | Biotech Hunter | Biotech Hunter